Pavel Andreea Licuta, Kundnani Nilima Rajpal, Morariu Stelian I, Tudor Anca, Man Dana Emilia, Duda-Seiman Daniel Marius, Velimirovici Dana Emilia, Valcovici Mihaela Daniela, Calin Pop, Dragan Simona Ruxanda
Department of Cardiology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, 300041, Romania.
Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes"University of Medicine and Pharmacy Timisoara 300310 Romania.
Int J Gen Med. 2024 Sep 24;17:4335-4346. doi: 10.2147/IJGM.S476736. eCollection 2024.
Over the years, troponins have aced the para-clinical tests for confirming the diagnosis of acute myocardial infarction. However, the rise in their levels is entirely time-dependent, which can cause a delay in the initiation of treatment protocols. Heart fatty acid binding protein (H-FABP) can serve comparatively as a better biological marker for overcoming this flaw of troponins, as it is quickly released into the bloodstream once the myocardial injury occurs due to decreased blood supply. This study aimed to evaluate the usefulness of this marker as well as establish the specificity and sensitivity of testing the H-FABP, if it adds to early diagnosis and can be relied upon in the future.
We evaluated 83 patients and their H-FABP levels, along with the standard cardiac markers like hsTni and CK-MB, in patients presenting with symptoms indicating an ongoing coronary event, who had presented to our hospital between August 2020 and June 2021. The patients were divided into two groups: group 1 comprised patients who had first medical contact within 4 hours of the onset of chest pain, and group 2 patients who had first medical contact after 4 hours of the appearance of symptoms. Statistical analysis was performed using MedCalc v20.023, considering statistical significance values of p <0.05. Results for targeted variables are presented using descriptive statistics (mean, standard deviation, range, median, and associated interquartile range) for continuous data, and counts with associated percentages for categorical data.
H-FABP was found to have better sensitivity and specificity of 89.67 and 95.65 in group 1 patients and 86.73 and 49.84, respectively, in group 2 patients. The other two cardiac biomarkers evaluated had lower values in response to H-FABP in the first 4 hours of presentation. Results for group 2 showed that specificitivity for hsTni is higher than that of H-FABP, that is, 69.98.
Heart fatty acid binding protein (H-FABP) should be included in the protocol for biochemical evaluation of all patients presenting to the emergency services with a suspicion of possible myocardial infarction. Early detection of this protein can help in effective and timely management of myocardial infarction, thus further decreasing mortality rates and the financial burden on healthcare systems worldwide.
多年来,肌钙蛋白在急性心肌梗死确诊的辅助临床检查中表现出色。然而,其水平升高完全依赖时间,这可能导致治疗方案启动延迟。心脏脂肪酸结合蛋白(H-FABP)相对而言可作为克服肌钙蛋白这一缺陷的更好生物标志物,因为一旦因供血减少发生心肌损伤,它会迅速释放到血液中。本研究旨在评估该标志物的效用,并确定检测H-FABP的特异性和敏感性,看其是否有助于早期诊断以及未来是否可信赖。
我们评估了2020年8月至2021年6月期间因出现提示正在发生冠状动脉事件的症状前来我院就诊的83例患者及其H-FABP水平,以及标准心脏标志物如高敏肌钙蛋白I(hsTni)和肌酸激酶同工酶(CK-MB)。患者分为两组:第1组为胸痛发作后4小时内首次就医的患者,第2组为症状出现4小时后首次就医的患者。使用MedCalc v20.023进行统计分析,以p<0.05作为统计学显著性值。连续数据的目标变量结果采用描述性统计(均值、标准差、范围、中位数及相关四分位间距)呈现,分类数据采用计数及相关百分比呈现。
发现第1组患者中H-FABP的敏感性和特异性分别为89.67和95.65,第2组患者中分别为86.73和49.84。在就诊后的前4小时,评估的其他两种心脏生物标志物与H-FABP相比数值较低。第2组结果显示,hsTni的特异性高于H-FABP,即69.98。
对于所有因疑似心肌梗死前来急诊的患者,心脏脂肪酸结合蛋白(H-FABP)应纳入生化评估方案。早期检测该蛋白有助于有效及时地管理心肌梗死,从而进一步降低死亡率以及全球医疗系统的经济负担。